Regentis Biomaterials Ltd. (NYSE:RGNT) — Stock Price
Regentis Biomaterials Ltd. (NYSE:RGNT) is currently trading at $2.10 USD, up 1.94% today. Over the past 52 weeks, shares have ranged between $1.74 and $2.23. This page tracks Regentis Biomaterials Ltd.'s live share price on the NYSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see Regentis Biomaterials Ltd. cash flow conversion.
Regentis Biomaterials Ltd. (RGNT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Regentis Biomaterials Ltd.'s daily closing share price and trading volume on the NYSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Regentis Biomaterials Ltd. Income Statement — Revenue, Profit & Earnings by Year
Regentis Biomaterials Ltd.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Research & Development | $331.00K | $-1.64 Million | $806.00K | $971.00K |
| SG&A | $8.29 Million | $712.00K | $1.12 Million | $436.00K |
| Total Operating Expenses | $8.62 Million | $-932.00K | $1.93 Million | $1.41 Million |
| Operating Income | $-8.62 Million | $932.00K | $-1.93 Million | $-1.41 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | $324.00K | $171.00K | $173.00K | $0.00 |
| Income Before Tax | $-13.65 Million | $4.80 Million | $-4.13 Million | $-1.45 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | $-13.65 Million | $4.80 Million | $-4.13 Million | $-1.45 Million |
Regentis Biomaterials Ltd. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Regentis Biomaterials Ltd.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $7.62 Million | $482.00K | $360.00K | $1.72 Million |
| Total Current Assets | $7.62 Million | $482.00K | $360.00K | $1.72 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | $2.87 Million | $41.59 Million | $46.27 Million | $43.78 Million |
| Total Current Liabilities | $2.87 Million | $6.49 Million | $3.14 Million | $2.61 Million |
| Long-term Debt | — | — | $7.41 Million | $6.47 Million |
| Net Debt | — | $4.72 Million | $7.27 Million | $5.23 Million |
| Total Stockholder Equity | $4.74 Million | $-41.10 Million | $-45.91 Million | $-42.06 Million |
| Retained Earnings | $-55.79 Million | $-42.15 Million | $-46.95 Million | $-42.81 Million |
Regentis Biomaterials Ltd. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Regentis Biomaterials Ltd. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | $-1.38 Million | $-641.00K | $-1.22 Million | $-1.50 Million |
| Capital Expenditures | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-1.38 Million | $-641.00K | $-1.22 Million | $-1.50 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | $8.52 Million | $525.00K | $325.00K | $0.00 |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | — | — | — | — |
| Depreciation | — | — | — | — |
| Change in Cash | $7.15 Million | $-116.00K | $-895.00K | $-1.50 Million |
Regentis Biomaterials Ltd. Earnings History — EPS Actual vs. Analyst Estimates
Track Regentis Biomaterials Ltd.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for Regentis Biomaterials Ltd..